导航

| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.04% | 1756/4773 |
| 近一周 | -1.57% | 539/5462 |
| 近一月 | 0.65% | 520/5421 |
| 近一季 | -2.82% | 1306/5209 |
| 近半年 | -13.99% | 3885/4920 |
| 近一年 | 9.22% | 1114/4366 |
| 近两年 | 41.13% | 1835/2954 |
| 近三年 | 23.72% | 1334/2253 |
| 成立以来 | 73.32% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
9.19% 93/4961 |
-6.60% 3721/5312 |
- - |
- - |
| 2025 | 14.59% 2600/4813 |
-2.41% 2882/3635 |
1.10% 2462/4076 |
9.66% 3338/4524 |
5.91% 389/4813 |
| 2024 | 14.85% 992/3463 |
7.28% 252/2808 |
0.72% 554/3014 |
9.84% 2662/3129 |
-3.24% 2301/3463 |
| 2023 | -2.06% 554/2656 |
12.81% 283/2280 |
0.42% 323/2385 |
-6.43% 1478/2515 |
-7.60% 2176/2655 |
| 2022 | -15.23% 412/2207 |
-8.86% 298/1919 |
4.64% 987/2016 |
-12.81% 786/2113 |
1.95% 1079/2208 |
| 2021 | 15.42% 307/1822 |
5.01% 123/1255 |
5.04% 828/1330 |
5.85% 253/1466 |
-1.15% 1318/1822 |
| 2020 | 14.81% 789/1250 |
-11.73% 848/1028 |
0.39% 1005/1067 |
15.90% 186/1164 |
11.79% 518/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 添富中证国企一带一路ETF VS. 长安沪深300非周期A(740101) |